Collegium Pharmaceutical (COLL) Non-Current Debt (2014 - 2026)

Collegium Pharmaceutical's Non-Current Debt history runs 13 years deep, the most recent figure standing at $531.7 million for Q1 2026.

• On a quarterly basis, Non-Current Debt fell 0.74% year-over-year to $531.7 million in Q1 2026; TTM through Mar 2026 was $531.7 million, a 0.74% decrease from a year earlier, with the FY2025 full-year figure at $542.1 million, down 1.57% from the prior year.
• Non-Current Debt declined to $531.7 million in Q1 2026 per COLL's latest filing, from $542.1 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $565.7 million in Q3 2024 and bottomed at $132.8 million in Q2 2024.
• The 5-year median for Non-Current Debt is $484.9 million (2022), against an average of $415.6 million.
• Across the five-year window, Non-Current Debt jumped 544.73% in 2022 and slumped 57.13% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $397.6 million in 2022, then plunged by 44.23% to $221.7 million in 2023, then jumped by 148.4% to $550.7 million in 2024, then decreased by 1.57% to $542.1 million in 2025, then decreased by 1.92% to $531.7 million in 2026.
• Per Business Quant, the three latest COLL Non-Current Debt figures stand at $531.7 million (Q1 2026), $542.1 million (Q4 2025), and $505.6 million (Q3 2025).